JPWO2021222355A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021222355A5
JPWO2021222355A5 JP2022565803A JP2022565803A JPWO2021222355A5 JP WO2021222355 A5 JPWO2021222355 A5 JP WO2021222355A5 JP 2022565803 A JP2022565803 A JP 2022565803A JP 2022565803 A JP2022565803 A JP 2022565803A JP WO2021222355 A5 JPWO2021222355 A5 JP WO2021222355A5
Authority
JP
Japan
Prior art keywords
seq
formulation
amino acid
acid sequence
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524444A5 (https=
JP2023524444A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029560 external-priority patent/WO2021222355A1/en
Publication of JP2023524444A publication Critical patent/JP2023524444A/ja
Publication of JP2023524444A5 publication Critical patent/JP2023524444A5/ja
Publication of JPWO2021222355A5 publication Critical patent/JPWO2021222355A5/ja
Priority to JP2025284219A priority Critical patent/JP2026047374A/ja
Pending legal-status Critical Current

Links

JP2022565803A 2020-04-29 2021-04-28 医薬製剤 Pending JP2023524444A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025284219A JP2026047374A (ja) 2020-04-29 2025-12-26 医薬製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017051P 2020-04-29 2020-04-29
US63/017,051 2020-04-29
PCT/US2021/029560 WO2021222355A1 (en) 2020-04-29 2021-04-28 Pharmaceutical formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025284219A Division JP2026047374A (ja) 2020-04-29 2025-12-26 医薬製剤

Publications (3)

Publication Number Publication Date
JP2023524444A JP2023524444A (ja) 2023-06-12
JP2023524444A5 JP2023524444A5 (https=) 2024-03-28
JPWO2021222355A5 true JPWO2021222355A5 (https=) 2024-03-28

Family

ID=76099009

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022565803A Pending JP2023524444A (ja) 2020-04-29 2021-04-28 医薬製剤
JP2025284219A Pending JP2026047374A (ja) 2020-04-29 2025-12-26 医薬製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025284219A Pending JP2026047374A (ja) 2020-04-29 2025-12-26 医薬製剤

Country Status (9)

Country Link
US (1) US20230167175A1 (https=)
EP (1) EP4142790A1 (https=)
JP (2) JP2023524444A (https=)
KR (1) KR20230004799A (https=)
CN (1) CN115484980A (https=)
AU (1) AU2021263813A1 (https=)
CA (1) CA3173706A1 (https=)
IL (1) IL297080A (https=)
WO (1) WO2021222355A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2019000225A1 (en) * 2017-02-02 2021-01-07 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
US9308257B2 (en) * 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
KR20180008921A (ko) * 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
DE102016124977B4 (de) 2016-12-20 2021-12-16 Endress+Hauser Flowtec Ag Verfahren zum Betreiben eines magnetisch-induktiven Durchflussmessgeräts und ein solches Durchflussmessgerät
TN2019000225A1 (en) * 2017-02-02 2021-01-07 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
MX2019013142A (es) * 2017-05-05 2019-12-16 Amgen Inc Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
CN110869050B (zh) * 2017-07-28 2024-07-02 豪夫迈·罗氏有限公司 双特异性抗体配制剂
WO2019064263A1 (en) * 2017-09-29 2019-04-04 Janssen Biotech, Inc. NOVEL FORMULATIONS FOR STABILIZING LOW DOSE ANTIBODY COMPOSITIONS

Similar Documents

Publication Publication Date Title
US20230047111A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
JP7590125B2 (ja) モノクローナル抗体製剤
JP2021512881A5 (https=)
US8246960B2 (en) Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6616931B1 (en) Rotavirus vaccine formulations
KR20090021298A (ko) 항-ｅｇｆｒ 항체의 동결건조 제제
EP2892504B1 (fr) Solution aqueuse de protéine à concentration élevée de viscosité réduite
US6403098B1 (en) Rotavirus vaccine formulations
JP2006510601A (ja) 抗原性が低下したポリマー結合体、その調製方法および使用方法
JP2006510601A5 (https=)
WO2000066160A1 (fr) Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
HUT53281A (en) Compositions absorbing through mycosa
JP2019509311A5 (https=)
EP0939648B1 (en) Rotavirus vaccine formulations
US20230414760A1 (en) Pharmaceutical formulation
CN108452319A (zh) 靶向cd20的抗体偶联药物制剂
JP2005532395A (ja) 新規な安定処方
JPWO2021222355A5 (https=)
WO2022242527A1 (zh) 一种单克隆抗体-细胞因子融合蛋白制剂
JPWO2021222347A5 (https=)
CN115721732B (zh) 抗体偶联药物的药物组合物、制剂及其制备方法、用途
JPWO2022046651A5 (https=)
CN113813377A (zh) 抗α4β7抗体制剂及其应用
JPWO2021081326A5 (https=)
JPWO2022256359A5 (https=)